313.22 0.00 (0.00%)
After hours: 4:06PM EDT
|Bid||310.00 x 1100|
|Ask||317.00 x 1100|
|Day's Range||313.00 - 322.14|
|52 Week Range||274.02 - 459.75|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||65.15|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||435.10|
Medical technology stocks hit record highs last year and are spiking in 2019. Four of the fastest growing among them have tacked on double-digit earnings growth for several years.
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.
Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.
Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.
Cardiovascular Systems (CSII) hopes that new product menu will deliver minimum 10% growth in its core business during the second half of fiscal 2019.
The hemodynamic support of Abiomed’s Impella heart pump platform for high-risk PCI and treatment of cardiogenic shock will be highlighted in more than 30 presentations and posters at the American College of Cardiology’s 68th Annual Scientific Session March 16-18, in New Orleans.
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.